🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Acadia Pharmaceuticals executive sells shares worth over $22k

Published 04/05/2024, 00:20
ACAD
-

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) disclosed in a recent filing that James Kihara, the company's Principal Accounting Officer, has sold a portion of his holdings in the company. The transaction, which took place on May 2, 2024, involved the sale of 1,326 shares of common stock at a weighted average price ranging from $16.94 to $17.03, resulting in a total value of approximately $22,462.

The sale was part of a prearranged trading plan intended to cover tax obligations related to the vesting of restricted stock units (RSUs). The RSUs represent a contingent right to receive shares of the company's common stock and are set to vest in four equal annual installments beginning May 1, 2024.

Following the transaction, Kihara's ownership in the company decreased, leaving him with a total of 14,370 shares of Acadia Pharmaceuticals' common stock. The company, headquartered in San Diego, California, is known for its work in the pharmaceutical preparations sector.

Investors often monitor insider transactions as they provide insights into executives' perspectives on their company's stock value. The recent sale by Kihara may attract attention from the market, considering his role as a key financial officer within Acadia Pharmaceuticals.

InvestingPro Insights

As investors dissect the recent insider transaction at Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), they may find it useful to consider some key metrics and insights provided by InvestingPro. Acadia's market capitalization stands at $2.82 billion, reflecting the company's size and market value as of the last twelve months ending Q4 2023. Despite the insider sale, Acadia's financial health appears robust, with a significant 40.45% revenue growth over the same period, indicating a strong upward trajectory in its financial performance.

Moreover, Acadia's stock is trading near its 52-week low, which could present a potential buying opportunity for value investors. The company's price to book ratio, while high at 6.52, may be justified by the growth and future prospects as the company holds more cash than debt on its balance sheet, a reassuring sign for risk-averse investors. Another positive indicator for the company is that analysts predict Acadia will become profitable within the year, aligning with expectations of net income growth.

For those considering a deeper dive into Acadia's financials and future outlook, InvestingPro offers additional insights. There are 6 more InvestingPro Tips available, including the company's liquid assets position and its ability to meet short-term obligations. These tips can be found at InvestingPro, and for those interested in a yearly or biyearly Pro and Pro+ subscription, use the coupon code PRONEWS24 to receive an additional 10% off.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.